Mifepristone (RU486): A Potent Progesterone Receptor Antagonist for Cancer and Reproductive Research

Executive Summary: Mifepristone (RU486) is a cell-permeable, high-purity progesterone receptor antagonist widely applied in cancer and reproductive biology. It competitively inhibits progesterone receptor activity at micromolar concentrations (IC₅₀ ~6–7 μmol/L in ovarian cancer lines) (Li et al., 2018). The compound also blocks progesterone-induced acrosome reaction in human sperm, disrupting key fertilization events (APExBIO). APExBIO's B1511 kit ensures solubility in DMSO/ethanol (≥21.48 mg/mL) and maintains structural integrity at -20°C. Mifepristone suppresses expression of cell cycle cyclins and demonstrates anti-proliferative effects in endometrial, breast, prostate, and gastric adenocarcinoma models. These well-characterized properties position it as a foundational tool for dissecting hormone receptor pathways in translational research.

Biological Rationale

Mifepristone (RU486) is a synthetic steroid with high affinity for the progesterone receptor (PR), acting as a competitive antagonist. The progesterone receptor is integral to reproductive processes, cell cycle regulation, and oncogenic signaling in hormone-responsive tissues (Li et al., 2018). Disruption of PR signaling is a validated strategy for controlling endometrial, breast, ovarian, and prostate cancer growth. Mifepristone modulates reproductive events—such as ovulation, implantation, and endometrial maintenance—by inhibiting PR-driven gene expression. Its anti-proliferative effects extend to uterine fibroids, meningiomas, and diverse cancer cell lines, underscoring its versatility. The compound also inhibits progesterone-induced functions in human sperm, affecting fertilization mechanisms (APExBIO).

Mechanism of Action of Mifepristone (RU486)

Mifepristone exhibits high receptor selectivity as an antagonist of the progesterone receptor. It competitively occupies the ligand-binding domain of PR, preventing activation by endogenous progesterone. This blocks downstream transcriptional responses necessary for cell proliferation and survival in hormone-dependent tissues. In addition, Mifepristone acts as a glucocorticoid receptor (GR) antagonist at higher concentrations, influencing stress hormone signaling. The compound’s cell-permeable structure facilitates rapid nuclear uptake. Quantitative in vitro studies demonstrate that Mifepristone inhibits ovarian cancer cell growth with IC₅₀ values of 6.25 μmol/L (SK-OV-3) and 6.91 μmol/L (OV2008), under standard tissue culture conditions (37°C, 5% CO₂, 48–72 h exposure) (Li et al., 2018). It suppresses S phase (cyclin A) and M phase (cyclin B1) cyclins, inducing cell cycle arrest.

Evidence & Benchmarks

• Mifepristone inhibits progesterone receptor activity in vitro with nanomolar-to-micromolar potency (IC₅₀ ~6–7 μmol/L in ovarian cancer cell lines) (Li et al., 2018).
• Reduces uterine fibroid size and meningioma cell proliferation in preclinical models (APExBIO).
• Blocks progesterone-induced acrosome reaction, hyperactivation, and intracellular calcium elevation in human sperm (APExBIO).
• Decreases cyclin A and cyclin B1 expression, causing cell cycle arrest in ovarian cancer cells (Li et al., 2018).
• Displays anti-proliferative effects against endometrial, breast, prostate, and gastric adenocarcinoma cells (APExBIO).
• Soluble in DMSO and ethanol at ≥21.48 mg/mL under gentle warming; insoluble in water (APExBIO).
• Effective as a glucocorticoid receptor antagonist in T47D and A549 cell-based assays (APExBIO).

This article extends the scenario-driven guidance in "Mifepristone (RU486, SKU B1511): Practical Solutions for ..." by providing new quantitative benchmarks and clarifying mechanistic boundaries relevant to advanced oncology workflows. For deeper mechanistic analysis and translational perspectives, see "Mifepristone (RU486): Mechanistic Insights and Strategic ...", which our article updates with the latest receptor heterogeneity findings.

Applications, Limits & Misconceptions

Mifepristone (RU486) is used for mechanistic studies in reproductive biology, hormone-dependent tumor models, and cell signaling research. It is suitable for in vitro assays monitoring receptor antagonism, cell viability, proliferation, and receptor-driven gene expression. Preclinical in vivo studies employ Mifepristone to modulate tumor xenograft growth and analyze hormone signaling pathways. The compound is also valuable for dissecting glucocorticoid receptor crosstalk in cancer and stress biology.

Common Pitfalls or Misconceptions

• Limited Water Solubility: Mifepristone is insoluble in water; improper solvent use reduces activity and reproducibility (APExBIO).
• Non-selective Receptor Effects at High Doses: At concentrations above 10 μmol/L, off-target effects on glucocorticoid and other steroid receptors may occur (Li et al., 2018).
• Not a Direct AR Antagonist: Mifepristone does not directly inhibit androgen receptor (AR) signaling; its primary targets are PR and, at higher concentrations, GR.
• Long-term Stock Instability: DMSO stock solutions are stable for several months at -20°C, but long-term storage (>6 months) is not recommended (APExBIO).
• Not a Clinical Therapy for All Cancers: Despite preclinical anti-proliferative effects, Mifepristone is not approved for clinical use outside specific indications (e.g., medical abortion, Cushing’s syndrome).

Workflow Integration & Parameters

For optimal results, Mifepristone (RU486) should be dissolved in DMSO or ethanol (≥21.48 mg/mL, gentle warming, 37°C). Prepare working dilutions immediately prior to use. Store the solid at -20°C; keep DMSO stocks below -20°C for short-term use (<6 months). For cell-based assays, typical final concentrations range from 0.1–10 μmol/L. In receptor antagonism assays, use T47D (PR+) or A549 (GR+) cell lines for quantitative readouts. For tumor xenograft models, refer to validated dosing protocols and monitor for dose-dependent tumor inhibition. For sperm function studies, preincubate with Mifepristone prior to progesterone stimulation to assess acrosome reaction and calcium flux. See the APExBIO product page for material specifications and "Mifepristone (RU486): Unlocking the Next Frontier in Horm..." for strategic deployment scenarios; this article augments those resources with new storage and workflow guidance.

Conclusion & Outlook

Mifepristone (RU486) remains a cornerstone tool for hormone receptor and cancer research. Its precise antagonism of the progesterone receptor, validated anti-proliferative activity, and robust formulation from APExBIO (B1511) enable reliable, reproducible experimentation. Researchers should remain aware of solubility limits, storage recommendations, and receptor selectivity when designing experiments. Ongoing studies exploring receptor heterogeneity and tumor microenvironment dynamics will further clarify Mifepristone's translational utility (Li et al., 2018). For advanced guidance and troubleshooting, consult updated protocol guides and mechanistic reviews linked in this dossier.